Myriad Genetics, Inc.’s MYGN MyRisk Hereditary Cancer Test with RiskScore study has been named as one of its top 10 significant advances in genomic medicine by the American Journal of Human Genetics....
Teleflex TFX recently launched its new Pressure Injectable Arrowg+ard Blue Plus MSB Procedure Kit in Europe, the Middle East and Africa (EMEA). This is regarded as a significant addition to the company’s...
Myriad Genetics, Inc.’s MYGN Prolaris prostate cancer prognostic test has been reinforced as an ‘Advanced Tool’ by the National Comprehensive Cancer Network (“NCCN”) in the fight against prostate...
Charles River Laboratories International, Inc. CRL has launched the Charles River Incubator Program (“CIP”) via its Global Innovation Center of Excellence (CoE). The initiative is designed to support...
Haemonetics: Fiscal Q2 Earnings Snapshot
Haemonetics: Fiscal Q1 Earnings Snapshot
Haemonetics: Fiscal Q4 Earnings Snapshot
Haemonetics: Fiscal Q3 Earnings Snapshot
/CNW/ - OpSens Inc. ("OpSens" or the "Corporation") (TSX: OPS) (OTCQX: OPSSF), a medical device cardiology-focused company delivering innovative solutions...
Announces that the Superior Court of Québec issued a final order today in connection with the previously ...